Pharmaceutical market of the EEU. The transition from national regulation to supra-national

A year has passed since the formal start of the whole pharmaceutical market of the EEU work


In May 2017 the pharmaceutical markets of five countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan and Russia) started working in a united format. The national regulatory systems for the admission of drugs to use, pharmacovigilance and quality of medicines have been standardized.


Valery Koreshkov, a Minister for Technical Regulation of the EEC, at the X Scientific and Practical Conference «Government Regulation and Russian Pharmaceutical Industry — 2018: Continuing the dialogue» has summarized the preliminary results of the work for the year, saying that «The Eurasian Economic Commission has fully prepared the regulatory legal base for the Eurasian Economic Union in the medical products circulation».


According to the Minister, in 2017 the volume of mutual trade between the allied states in comparison with 2016 has grown up to $473,6 million. «A tremendous amount of work has been done for the year in preparing documents. We took into account the advanced scientific approaches in the field of safety regulation, quality and effectiveness of medicines, the desire to comply with the world standards of pharmaceutical regulation was taken as an impulse».


«It should be noted that there is a transitional period, ensuring a smooth transition from national to unified regulation. This will prevent disruptions in the healthcare systems of the EAEU countries and will help manufacturers to adapt to new requirements as comfortably as possible» — Valery Koreshkov said. Viktor Dmitriev, the General Director of the ARPM expressed the hope that the market will work effectively for the benefit of patients, business and government. Moreover, all the backgrounds for this exist and most of the work has already been done.

Пресс-служба АРФП